PPARG and hypertensive disorder: In addition, systemic activation of PPARγ by its agonist has been shown to prevent the progression of multiple cardiovascular diseases, such as hypertension, atherosclerosis, and chronic kidney disease by reducing inflammation and downregulating angiotensin II (AngII)-induced Ang II type 1 receptor (AT1R) expression [5–8].